Increased cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine in human leukemic cell-lines after a preincubation with Cyclopentenyl cytosine

被引:12
|
作者
Verschuur, AC
Van Gennip, AH
Leen, R
Van Kuilenburg, ABP
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, Div Clin Chem, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, Div Pediat, NL-1100 DE Amsterdam, Netherlands
[3] Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1100 DE Amsterdam, Netherlands
来源
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2004年 / 23卷 / 8-9期
关键词
Cyclopentenyl cytosine; CPEC; gemcitabine; leukemia; CTP synthetase;
D O I
10.1081/NCN-200027733
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The in vitro modulating effect of Cyclopentenyl cytosine (CPEC) on the metabolism of gemcitabine was studied in lymphocytic and myeloid leukemic cell-lines. In MOLT-3 cells, that were pretreated with CPEC, the incorporation of 2',2'-difluoro-2'-deoxycytidine triphosphate (dFdCTP) into DNA was significantly increased by 57-99% in comparison with cells that were only treated with gemcitabine. The increased incorporation of dFdCTP into DNA in CPEC pretreated cells was paralleled by an increase in apoptotic and necrotic cells of 17-34%. In HL-60 cells that were preincubated with CPEC, increased concentrations of the mono-/di- and triphosphate form of gemcitabine were observed, as well as an increased incorporation of dFdCTP into DNA (+773%). This increased incorporation was paralleled by a significant increase in apoptosis and necrosis. We conclude that CPEC enhances the incorporation of dFdCTP into DNA and thus increases the cytotoxicity of gemcitabine in lymphocytic and myeloid leukemic cell-lines.
引用
收藏
页码:1517 / 1521
页数:5
相关论文
共 45 条
  • [41] Time-course of butyric acid-induced differentiation in human K562 leukemic cell line: rapid increase in gamma-globin, porphobilinogen deaminase and NF-E2 mRNA levels
    Chenais, B
    Molle, I
    Trentesaux, C
    Jeannesson, P
    LEUKEMIA, 1997, 11 (09) : 1575 - 1579
  • [42] Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro
    Kawasaki, Daisuke
    Emori, Yutaka
    Eta, Runa
    Iino, Yuka
    Hamano, Hiroki
    Yoshinaga, Koji
    Tanaka, Takao
    Takei, Mineo
    Watson, Susan A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 883 - 892
  • [43] Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro
    Daisuke Kawasaki
    Yutaka Emori
    Runa Eta
    Yuka Iino
    Hiroki Hamano
    Koji Yoshinaga
    Takao Tanaka
    Mineo Takei
    Susan A. Watson
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 883 - 892
  • [44] All-trans retinoic acid enhances the effect of 5-aza-2′-deoxycytidine on p16INK4a demethylation, and the two drugs synergistically activate retinoic acid receptor β gene expression in the human erythroleukemia K562 cell line
    Xiang, Lili
    Dong, Weimin
    Wang, Rong
    Wei, Jiang
    Qiu, Guoqiang
    Cen, Jiannong
    Chen, Zixing
    Zheng, Xiao
    Hu, Shaoyan
    Xie, Xiaobao
    Cao, Xiangshan
    Gu, Weiying
    ONCOLOGY LETTERS, 2014, 8 (01) : 117 - 122
  • [45] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
    Miller, Vincent A.
    Hirsh, Vera
    Cadranel, Jacques
    Chen, Yuh-Min
    Park, Keunchil
    Kim, Sang-We
    Zhou, Caicun
    Su, Wu-Chou
    Wang, Mengzhao
    Sun, Yan
    Heo, Dae Seog
    Crino, Lucio
    Tan, Eng-Huat
    Chao, Tsu-Yi
    Shahidi, Mehdi
    Cong, Xiuyu Julie
    Lorence, Robert M.
    Yang, James Chih-Hsin
    LANCET ONCOLOGY, 2012, 13 (05): : 528 - 538